Teva and Alvotech launch SIMLANDI in US for arthritis
This marks the first biosimilar launched under the strategic partnership between the two companies. SIMLANDI has been approved by the US Food and Drug Administration (FDA) as the
Basilea Pharmaceutica has received an additional $7.3m from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its antibiotic candidate, BAL2420, towards first-in-human clinical trials expected by mid-2026.